Dose Escalation and Treatment Patterns of Advanced Therapies Used to Treat Ulcerative Colitis: A Retrospective Database Analysis in the United States

Smith, Timothy W.; DiBonaventura, Marco; Gruben, David; Bargo, Danielle; Salese, Leonardo; Quirk, Daniel

doi:10.14309/00000434-201810001-00622

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study found that between 10-40% of patients, depending upon the specific biologic used, increased the dose and/or the frequency of administration during maintenance. This is generally consistent with studies in the US using administration claims data, which reported rates between 24-39% for ADA, IFX, and VEDO [17]. Rubin and colleagues 2017 reported slightly lower rates (13% and 29% for ADA and IFX, respectively) though they used a more restrictive definition; patients needed to have used double the daily dose for this to be considered an escalation [13].…”

Section: Discussionsupporting

confidence: 76%

“…Our study suggests that between 10-30% of patients use combination therapy, depending upon the specific biologic used (and, potentially, the line of therapy). This is slightly lower than rates reported from a recent US administrative claims database [17]. However, the data collection form encouraged physicians to consider any add-on of therapy to be a new line so if the IM was not administered concomitantly with the biologic therapy then the database would not consider this combination therapy.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

et al. 2020

Self Cite

View full text Add to dashboard Cite

The aim of the present study is to examine how moderate-to-severe ulcerative colitis (UC) is currently managed in real-world clinical practice across the United States (US) and European Union Five (EU5; France, Germany, Italy, Spain, and the United Kingdom). Methods Data from the 2017 Adelphi Inflammatory Bowel-Disease Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of patient chart information abstracted by selected gastroenterologists across the US and EU5. Eligible gastroenterologists who agreed to participate were asked to complete patient record forms for the next seven consecutive eligible adult patients with UC. Only charts from patients with moderate-tosevere UC were included in the analysis (defined as those with documented administration of either an immunosuppressant [IM] or a biologic). Treatment patterns were reported descriptively. Results 411 and 1191 patient charts were included in the US and EU5 (mean ages 44.2 and 39.6 years; 53.0% and 43.5% female), respectively. For those with complete treatment history, 40.7% and 52.9% used either an IM or biologic as their first treatment (with or without steroids). Usage of these therapies increased in subsequent lines. The percentage of patients treated with combination therapy (i.e., biologic therapy with a concomitant IM) in first line generally varied between 10-20% (e.g., US: adalimumab (ADA), 10.8%; infliximab (IFX), 18.2%; EU5: ADA, 12.5%; IFX, 19.9%), though increased in later lines in the EU5. Among

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 82%

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, in both CD and UC subgroups, the option of prescribing combination treatment, was superficially found to be underrated, as only 3.6% of patients were under this treatment. Nevertheless, 13.57% of all patients under anti-TNFα treatment were receiving an immunosuppressant agent (Table 1), a figure falling in the range of real word recent data, which show a respective percentage of 10–30% in both USA and Europe [34,35].…”

Section: Discussionmentioning

confidence: 99%

Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center

Kyriakos

Papaefthymiou

Giakoumis

et al. 2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background The prevalence and incidence of inflammatory bowel diseases (IBDs) vary among countries. Data regarding prevalence of IBD in Greece are limited or outdated. Methods We reviewed the medical records of IBD patients from a population of 551,808 Greek Army recruits in a 13-year period (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018). Study population consisted of males 18-37 of age from Northwest, Central Greece (including Attica), Peloponnese, and Aegean Sea Islands. Age, disease distribution, pharmaceutical treatment and IBD-related surgery at the time of patients' admission were recorded. Results The prevalence of IBD among male recruits during the studied period was 0.15% (839/551 808, 95% confidence interval 0.14-0.16%). Of these, 448 (53.4%) had Crohn's disease (CD) and 391 (46.6%) ulcerative colitis (UC). Although 32.1% of CD patients had been treated with biologics, most often infliximab (60% of them), azathioprine was the most common as monotherapy (27% of patients). Among UC patients, mesalamine was the most often prescribed treatment (64.2%), whereas treatment with biologics as monotherapy or in combination with azathioprine was used in a ratio 1:2 compared to CD patients. A gradual reduction in steroid use was noted from 2006 to 2018, coinciding with the advent and increasing use of biologics. IBD-related surgery had been performed in 8% and 2.8% of CD and UC patients, respectively. Conclusion The prevalence of IBD in Greek male recruits was 0.15% with a slight CD predominance. Remarkable changes in therapeutic trends were noted with an increasing use of biologics and reduced prescription of steroids, especially for CD. Eur

show abstract

Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases

Sah

Teeple

Muser

et al. 2022

Current Medical Research and Opinion

View full text Add to dashboard Cite

Dose Escalation and Treatment Patterns of Advanced Therapies Used to Treat Ulcerative Colitis: A Retrospective Database Analysis in the United States

Cited by 3 publications

References 0 publications

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

Prevalence of inflammatory bowel disease in young Greek Army male recruits from 2006 to 2018: a 13-year retrospective study from a tertiary center

Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases

Contact Info

Product

Resources

About